ACE and heart failure: The deleterious effects of sustained RAAS activation on the development of heart failure are counteracted by angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blocker (ARB), and mineralocorticoid-receptor antagonist (MRA) [2–4].